Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? - Wikidata - awgldk - TriplyDB

Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?

Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?

http://www.wikidata.org/entity/Q37364945

about

Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials Patient preferences in the treatment of diabetic retinopathy.Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus.Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trial Effectiveness and safety of Humalog Mix 50/50 versus Humalog Mix 75/25 in Chinese patients with type 2 diabetes β-cell function preservation after 3.5 years of intensive diabetes therapy Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes.Insulin use, prescription patterns, regimens and costs.-a narrative from a developing country.Facilitating healthy coping in patients with diabetes: a systematic review.A real-world study of the effect of timing of insulin initiation on outcomes in older medicare beneficiaries with type 2 diabetes mellitus.Early insulinization to prevent diabetes progression.Knowledge of insulin use and its determinants among Nigerian insulin requiring diabetes patients Pioglitazone: beyond glucose control.The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus.Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes.Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes.Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps.New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals.Efficacy of structured education in patients with type 2 diabetes mellitus receiving insulin treatment.Barriers to achieving glycemic targets: who omits insulin and why?Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study.Persistence with rapid-acting insulin and its association with A1C level and severe hypoglycemia among elderly patients with type 2 diabetes.Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years.The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin.An evaluation of the impact of antidiabetic medication on treatment satisfaction and quality of life in patients of diabetes mellitus.Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice.

P2860

Q26767164-11F7319C-390E-47B5-B952-2A0C2C65BCC2 Q33928715-B5795690-D3AF-4E2F-91C2-51AD28ADAC70 Q34242531-F6D61AC1-4A3E-4547-8081-C07CF4CE6A49 Q34374321-A643342F-F2CB-4BF3-A2D9-A0C6079BAF15 Q34507074-37FC093D-5243-4C23-AAC7-78933E08787C Q34586302-C54A9534-1378-4278-9654-D85F19220A4E Q34783357-086605DF-0A4C-4726-BF03-2BD53D18FF8D Q36047178-2584F9FB-D54C-4A8A-9F12-0C08AEC5377B Q36252697-3C2A1529-9F71-4E5C-B495-E8651C74618F Q36513336-ADB24AD8-1AA9-4F0A-97B9-C65F2A0DBB79 Q36545261-1E123F9B-D5F7-4646-81E4-DE7BC6F25308 Q36971385-B9AC68E6-3F1C-4242-9B8B-7F4346BBC325 Q37577178-5512BF37-6ECD-4F08-BD39-1FE3A4502215 Q37601770-63032F19-E916-4704-963F-840199D73199 Q37776510-1602C5E2-4408-44B3-897C-6B2C612A8FAC Q37915625-DFC15440-9675-4030-8400-5980DE2D858B Q38095652-A4FB9221-2D14-4B83-9DB1-E2E4465861BB Q38115799-6983D732-16DF-4425-B5EE-D62E67691C39 Q38129446-2C533E6A-396C-4C83-BB98-7EC077433003 Q38246691-7309CEB2-5715-4A78-94B9-F2BE0BC4638B Q42171251-FB1A3F4D-1577-4E6D-8E34-8CED7DC9B32A Q42630239-0421FB13-13F2-4371-81A6-F3A176F4B434 Q42933616-789B079F-73AB-40E6-AEE1-47DA83BE40B8 Q44264038-BF0A7DF2-946A-4D1F-A435-0B302567D3E8 Q45056742-C59FD5BD-4D63-4E53-B0F5-D2C3190F02B2 Q48086602-A627FF4A-E6BA-4331-B3B7-B4FD20E396FE Q48287418-0F0A55F8-19C9-4853-B000-348473285658 Q49742224-61F766A2-9626-4B3A-AE4F-AC9A176A0252 Q51185982-A4173548-D90F-4735-9ED3-8383545AEE4F Q55288083-8DC0C686-149D-418D-AD53-573CFC5C545A

P2860

Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?

http://www.wikidata.org/entity/Q37364945

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Insulin-based versus triple or ...... e 2 diabetes: which is better?

@en

Insulin-based versus triple or ...... e 2 diabetes: which is better?

@nl

type

label

Insulin-based versus triple or ...... e 2 diabetes: which is better?

@en

Insulin-based versus triple or ...... e 2 diabetes: which is better?

@nl

prefLabel

Insulin-based versus triple or ...... e 2 diabetes: which is better?

@en

Insulin-based versus triple or ...... e 2 diabetes: which is better?

@nl

P1433

Q37364945-F54CB163-569D-4E08-843A-5766F9CAC0DB

P1476

Q37364945-F44DA504-ACD7-4431-A255-841060D098CB

P2093

Q37364945-644E3DDB-BA9E-4029-AA59-7670C492DB00

Q37364945-73E03DAE-493C-4F5F-87BF-A8A9681837FC

Q37364945-8D1D965D-C073-4FBC-BB50-51EE68165B2D

Q37364945-90B446B5-7FFD-4A11-B9D8-5BCEE7AAC8D2

Q37364945-A5E3B547-7477-4981-8433-C0E908FA41FF

Q37364945-F278005D-6B6C-4CCD-9D56-1F7581BBF130

P2860

Q37364945-1A8FCA12-F097-4BFA-B5E9-B5C143726839

Q37364945-2589834B-737C-4207-A8EA-B5844CB5B79B

Q37364945-302E0505-0F8C-4252-AF8C-6616824B1D62

Q37364945-31BFEB29-860E-409E-966A-CF05956DD39A

Q37364945-3542A5D9-D3B8-4D97-89C9-41EEADCBC0DB

Q37364945-37F5524A-FE41-4CB7-9C33-7853BFCF9DA9

Q37364945-472EFCC3-DD60-4B40-A9B1-FEFC1ECAB89D

Q37364945-609FDD2C-AEE1-48F2-B18E-7C329C97BB32

Q37364945-81917249-39E2-4ED6-9263-6A8078B4396A

Q37364945-9C20F7E4-AA8A-4E63-890F-4394ECFD9853

P304

Q37364945-61AB2FE6-DBEE-4AE0-AEDD-F2406D49C4A0

P31

Q37364945-9803E3BC-254A-4E69-9E99-7537F4EC0F9D

P356

Q37364945-C288C13A-9287-463C-AF48-7094373B8408

P407

Q37364945-A30F8953-0AED-4B80-83D5-7AE7C3AC858E

P433

Q37364945-9F84573F-25AA-420D-AC99-01A727A3E83B

P478

Q37364945-486B6AB4-5959-4205-8F02-E7D1AFDB39CF

P577

Q37364945-40BCEF59-0F05-4DB9-969D-A570C5BFA031

P5875

Q37364945-2684B56C-DCDC-4358-A01D-65885A2CD538

P698

Q37364945-C2DBA1C4-F187-43CD-840F-679E88F0401A

P921

Q37364945-07A5CB0C-CC61-4FE4-BA58-131F78F07E58

Q37364945-946109C5-4C40-420D-BA09-2629A6A9EA03

P932

Q37364945-8034CE50-3DFA-401F-8C74-3281B38C71E8

P356

P1433

P1476

Insulin-based versus triple or ...... e 2 diabetes: which is better?

@en

P2093

Beverley Adams-Huet

http://www.w3.org/2001/XMLSchema#string

Ildiko Lingvay

http://www.w3.org/2001/XMLSchema#string

Jaime L Legendre

http://www.w3.org/2001/XMLSchema#string

Philip Raskin

http://www.w3.org/2001/XMLSchema#string

Polina F Kaloyanova

http://www.w3.org/2001/XMLSchema#string

Song Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities.

Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion.

Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

A rapid increase in beta-cell function by multiple insulin injections in type 2 diabetic patients is not further enhanced by prolonging treatment.

Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients.

P304

1789-1795

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC09-0653

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26661574

http://www.w3.org/2001/XMLSchema#string

P698

19592630

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2752924

http://www.w3.org/2001/XMLSchema#string